Quantifying mutated and unmutated BCR-ABL transcripts confirms suitability of direct sequencing sensitivity in mutation analysis of patients with chronic myeloid leukemia with secondary resistance to tyrosine kinase inhibitors, regardless of ratio values

Leuk Lymphoma. 2010 Feb;51(2):350-4. doi: 10.3109/10428190903470349.
No abstract available

Publication types

  • Letter

MeSH terms

  • DNA Mutational Analysis / methods*
  • Drug Resistance, Neoplasm / genetics
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Mutation
  • Protein Kinase Inhibitors / therapeutic use*

Substances

  • Protein Kinase Inhibitors
  • Fusion Proteins, bcr-abl